@prefix : <http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia> .

<http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia> rdf:type owl:Ontology ;
                                                                    owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                    rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255499/"^^xsd:anyURI ;
                                                                    rdfs:label "Atomoxetine and Dystonia in paediatric patients"^^xsd:Literal ;
                                                                    owl:versionInfo "draft-v0.95-20211109"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


###  http://purl.org/mp/supportedBy
mp:supportedBy rdf:type owl:ObjectProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ADRs_for_atomoxetine_from_clinical_trials
:ADRs_for_atomoxetine_from_clinical_trials rdf:type owl:NamedIndividual ,
                                                    OpenPVSignal:Clinical_trial_information ,
                                                    OpenPVSignal:Warning_Information ;
                                           OpenPVSignal:refers_to_adverse_effect :decreased_apetite ,
                                                                                 :decreased_weight ,
                                                                                 :depression ,
                                                                                 :dizziness ,
                                                                                 :gastrointestinal_reactions ,
                                                                                 :increasedBloodPressure ,
                                                                                 :increasedHeartRate ,
                                                                                 :insomnia ,
                                                                                 :irritability ,
                                                                                 :moodSwings ,
                                                                                 :skinReactions ,
                                                                                 :somnolence ;
                                           OpenPVSignal:refers_to_drug :atomoxetin ;
                                           mp:references :Ref.1 ;
                                           OpenPVSignal:has_content "The most frequent adverse  reactions reported during clinical trials of  atomoxetine in children and adolescents include  gastrointestinal reactions, increased blood  pressure and heart rate, decreased appetite,  decreased weight and skin reactions. Common  neuropsychiatric reactions reported included  dizziness, mood swings, somnolence, insomnia,  irritability and depression.1" ;
                                           rdfs:label "ADRs for atomoxetine from clinical trials" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#AtomoxetineAndADHD
:AtomoxetineAndADHD rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug_Usage ;
                    OpenPVSignal:concerns_indication_for_use :attentionDeficitHyperactivityDisorder ;
                    OpenPVSignal:refers_to_drug :atomoxetin ;
                    rdfs:label "Atomoxetine and ADHD" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#AtomoxetineAndNeuropsychiatricFrequentAE
:AtomoxetineAndNeuropsychiatricFrequentAE rdf:type owl:NamedIndividual ,
                                                   OpenPVSignal:Warning_Information ;
                                          OpenPVSignal:refers_to_adverse_effect :dizziness ,
                                                                                :headache ,
                                                                                :hypoaesthesia ,
                                                                                :insomnia ,
                                                                                :paraesthesia ,
                                                                                :sedation ,
                                                                                :seizures ,
                                                                                :somnolence ,
                                                                                :syncope ,
                                                                                :tics ,
                                                                                :tremor ;
                                          OpenPVSignal:refers_to_drug :atomoxetin ;
                                          mp:references :Ref.1 ;
                                          rdfs:label "product literature" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Atomoxetine_and_Dystonia_in_paediatric_patients
:Atomoxetine_and_Dystonia_in_paediatric_patients rdf:type owl:NamedIndividual ,
                                                          OpenPVSignal:Pharmacovigilance_Signal_Report ;
                                                 OpenPVSignal:refers_to_author :Dr_Ian_Boyd ;
                                                 OpenPVSignal:refers_to_signal :pvSignal ;
                                                 OpenPVSignal:has_creation_date "01/08/2015" ;
                                                 OpenPVSignal:has_overall_conclusion "causal association most probable" ;
                                                 rdfs:label "Atomoxetine and Dystonia in paediatric patients" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ConclusionContent
:ConclusionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Conclusion ;
                   OpenPVSignal:has_content "In summary, there are 31 reports associating dystonia with the use of atomoxetine from children and adolescents. Atomoxetine was the only drug suspected in 21 of the 31 cases. The fact there was a positive dechallenge in 13 of the 16 reports where recovery was documented is suggestive of a drug-induced effect. However, the possible association of atomoxetine with dystonia appears restricted to the adolescent and paediatric population. A possible mechanism may be based on inhibition of dopamine uptake." ;
                   rdfs:label "Conclusion content" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#DiscussionContent
:DiscussionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Discussion ;
                   mp:references :Ref.3 ,
                                 :Ref.4 ;
                   OpenPVSignal:has_content "Case reports in VigiBaseÂ® suggest that there is a possible signal for the association of atomoxetine and dystonia in children and adolescents. Atomoxetine was the only drug suspected in 21 of the 31 cases. In the remaining 10 cases, other suspected drugs would appear to be a more likely cause in seven reports but atomoxetine would appear an equally likely cause in the other three cases. Time to onset was reported in only two of the reports and ranged from the same day the drug was administered to 24 days. The outcome of the dystonia was indicated in 17 reports. The patients were reported as recovered or recovering in 16 cases and not recovered in the remaining case. In the cases where recovery was reported, the drug was withdrawn in 13 cases, continued in one case and the fate of the drug was unknown in the remaining two cases. In the case where the patient had not recovered, the drug was continued. The fact there was a positive dechallenge in 13 of the 16 reports where recovery was documented is suggestive of a druginduced effect. The possible association of atomoxetine with dystonia appears restricted to the adolescent and paediatric population. There is a total of 33 reports of dystonia in association with atomoxetine in the total population where the age is known. Thirtyone of these reports were reported in the adolescent and paediatric age groups which represents 93.9% of all the reports. While it may be considered that atomoxetine is used preferentially in the younger age groups, overall reporting in VigiBaseÂ® indicates that of the 16,592 reports submitted, the age group from 2 to 17 years represents 72.3% of the total reports in which the age is known. The pathophysiological mechanisms underlying acute extrapyramidal symptoms such as dystonia are usually attributed to the effects of dopamine receptor blockade in the basal ganglia.4 As atomoxetine is a weak inhibitor of dopamine uptake, it is possible that this may be the basis of a possible mechanism. It is also possible that children and adolescents may be at greater risk as it is known that younger age is a risk factor for the development of dystonia in patients receiving antipsychotic treatment.3 " ;
                   rdfs:label "Discussion content" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#DosageContent
:DosageContent rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Dosage ;
               OpenPVSignal:refers_to_drug :atomoxetin ;
               OpenPVSignal:has_content "Dosage ranged from 10 mg to 160 mg (median: 25 mg) in the 16 cases which reported this information." ;
               rdfs:label "Dosage content" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Dr_Ian_Boyd
:Dr_Ian_Boyd rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Author ;
             OpenPVSignal:has_first_name "Ian" ;
             OpenPVSignal:has_last_name "Boyd" ;
             rdfs:label "Dr Ian Boyd" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Dystonia
:Dystonia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Free_text_reporting_element ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ;
          mp:references :Ref.2 ;
          OpenPVSignal:has_content "Dystonia denotes abnormal movements that are slow or so sustained that they may appear as abnormal postures. These abnormal movements of groups of muscles or body segments include grimacing, torticollis, blepharospasm and limb torsions. Generally, they are absent during sleep and exacerbated by emotional stress or voluntary activity. Dystonia occurs as an occasional complication of treatment with neuroleptic and dopaminergic drugs and many others. Drug-induced dystonia may be early (onset within one week of commencement of treatment) or late (onset after several weeks, months or years of treatment). Late persistent dystonia is usually termed tardive dyskinesia.2 Dystonia is a preferred term in WHO-ART with a number of included terms including trismus and various spasms (facial, infantile, cervical, oropharyngeal, tongue). Â " ;
          rdfs:label "Dystonia" ,
                     "Dystonia pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#IntroductionContent
:IntroductionContent rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Introduction ;
                     mp:references :Ref.1 ,
                                   :Ref.2 ;
                     OpenPVSignal:has_content "Atomoxetine is a relatively potent inhibitor of the presynaptic noradrenaline transporter, a moderate inhibitor of 5HT uptake, and a weak inhibitor of dopamine uptake with minimal affinity for the other noradrenergic receptors. Atomoxetine has moderate affinity for 5HT2 and GABAA receptors but poor affinity for most other receptors. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as defined by DSMIV criteria in children 6 years of age and older, adolescents and adults. The most frequent adverse reactions reported during clinical trials of atomoxetine in children and adolescents include gastrointestinal reactions, increased blood pressure and heart rate, decreased appetite, decreased weight and skin reactions. Common neuropsychiatric reactions reported included dizziness, mood swings, somnolence, insomnia, irritability and depression.1 Dystonia denotes abnormal movements that are slow or so sustained that they may appear as abnormal postures. These abnormal movements of groups of muscles or body segments include grimacing, torticollis, blepharospasm and limb torsions. Generally, they are absent during sleep and exacerbated by emotional stress or voluntary activity. Dystonia occurs as an occasional complication of treatment with neuroleptic and dopaminergic drugs and many others. Druginduced dystonia may be early (onset within one week of commencement of treatment) or late (onset after several weeks, months or years of treatment). Late persistent dystonia is usually termed tardive dyskinesia.2 Dystonia is a preferred term in WHO-ART with a number of included terms including trismus and various spasms (facial, infantile, cervical, oropharyngeal, tongue). " ;
                     rdfs:label "Introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Literature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Literature_information ;
                          mp:references :Ref.1 ;
                          OpenPVSignal:has_content """The product literature does not refer to dystonia
although it does mention that very common,
common or uncommonly reported neurological
reactions included headache, dizziness,
somnolence including sedation, insomnia, syncope
and tremor. Post-marketing adverse neurological
events reported very rarely include seizures,
paraesthesia in children and adolescents,
hypoaesthesia and tics.1 No reports of dystonia in
association atomoxetine could be found in the
literature.""" ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#MechanismOfAtomoxetine
:MechanismOfAtomoxetine rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Mechanism ;
                        mp:references :Ref.1 ;
                        OpenPVSignal:has_content "Atomoxetine is a relatively potent inhibitor of the presynaptic noradrenaline transporter, a moderate inhibitor of 5HT uptake, and a weak inhibitor of dopamine uptake with minimal affinity for the other noradrenergic receptors. Atomoxetine has moderate affinity for 5HT2 and GABAA receptors but poor affinity for most other receptors." ;
                        rdfs:label "Mechanism of atomoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#OverallReportsInVigibase
:OverallReportsInVigibase rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:refers_to_adverse_effect :dystonia ;
                          OpenPVSignal:refers_to_drug :atomoxetin ;
                          OpenPVSignal:has_count 40 ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          rdfs:label "Overall reports in vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 10 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 12 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient11
:Patient11 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 9 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient12
:Patient12 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 9 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient13
:Patient13 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 10 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 13" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient14
:Patient14 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 17 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 14" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient15
:Patient15 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 13 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 15" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient16
:Patient16 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 8 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 16" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient17
:Patient17 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 10 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 17" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient18
:Patient18 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 8 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 18" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient19
:Patient19 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 5 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 19" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 16 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient20
:Patient20 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 11 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 20" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient21
:Patient21 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 6 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 21" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient22
:Patient22 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 15 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 22" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient23
:Patient23 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 15 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 23" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient24
:Patient24 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 9 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 24" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient25
:Patient25 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 5 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 25" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient26
:Patient26 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 9 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 26" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient27
:Patient27 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 8 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 27" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient28
:Patient28 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 9 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 28" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient29
:Patient29 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 13 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 29" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 10 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient30
:Patient30 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 5 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 30" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient31
:Patient31 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 5 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 31" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 7 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 9 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 16 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 15 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 16 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 8 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient_a
:Patient_a rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 51 ;
           rdfs:label "Patient a" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Patient_b
:Patient_b rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 24 ;
           rdfs:label "Patient b" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#PercentageOfatomoxetine-dystoniaCasesForAdolescents
:PercentageOfatomoxetine-dystoniaCasesForAdolescents rdf:type owl:NamedIndividual ,
                                                              OpenPVSignal:Statistical_Entity ;
                                                     OpenPVSignal:refers_to_adverse_effect :dystonia ;
                                                     OpenPVSignal:refers_to_drug :atomoxetin ;
                                                     OpenPVSignal:has_value 0.939 ;
                                                     rdfs:label "Percentage of atomoxetine-dystonia cases for adolescents" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#PossibleMechanismOfatomoxetine-inducedDystonia
:PossibleMechanismOfatomoxetine-inducedDystonia rdf:type owl:NamedIndividual ,
                                                         OpenPVSignal:Adverse_Effect_Mechanism ;
                                                OpenPVSignal:refers_to_adverse_effect :dystonia ;
                                                mp:references :Ref.4 ;
                                                OpenPVSignal:has_content "The pathophysiological mechanisms underlying acute extrapyramidal symptoms such as dystonia are usually attributed to the effects of dopamine receptor blockade in the basal ganglia.4 As atomoxetine is a weak inhibitor of dopamine uptake, it is possible that this may be the basis of a possible mechanism." ;
                                                rdfs:label "Possible mechanism of atomoxetine-induced dystonia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Therapeutic Goods Administration. Product Information for Strattera. URL: https://www.ebs.tga.gov.au/ebs/ picmi/picmirepository.nsf/pdf?OpenAgent&id= CP2010-PI-04269-3. Accessed: 30 January 2015. " ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "The Council for International Organizations of Medical Sciences (CIOMS). Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for their Use. CIOMS, Geneva, 1999. URL: http://www.cioms.ch/publications/ reporting_adverse_drug.pdf. Accessed: 30 January 2015. " ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molena JA. Drug-induced movement disorders. Drug Saf. 1997;16:180-204. " ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Casey DE. Neuroleptic drug-induced extrapyramidal symptoms and tardive dyskinesia. Schizo Res 1991;4:109-20. " ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :drugInteraction ,
                                               :drugLevelDecreased ,
                                               :dystonia ,
                                               :eegAbnormal ,
                                               :mentalStatusChanges ,
                                               :muscleContractionsInvoluntary ,
                                               :salivaIncreased ,
                                               :somnolence ;
         OpenPVSignal:refers_to_concomitant_drug :buspirone ,
                                                 :citalopram ,
                                                 :diphenhydramine ,
                                                 :methylphenidate ,
                                                 :risperidone ,
                                                 :valproicAcid ;
         OpenPVSignal:refers_to_patient :Patient1 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report10
:Report10 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :blepharospasm ,
                                                :dyskinesia ,
                                                :dystonia ,
                                                :pruritus ,
                                                :therapeuticResponseIncreased ;
          OpenPVSignal:refers_to_patient :Patient10 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report11
:Report11 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ;
          OpenPVSignal:refers_to_patient :Patient11 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :bupropion ,
                                                        :oxcarbazepine ,
                                                        :quetiapine ,
                                                        :risperidone ,
                                                        :valproicAcid ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report12
:Report12 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :anorexia ,
                                                :choreoathetosis ,
                                                :convulsionsGrandMal ,
                                                :dystonia ,
                                                :jawDisorder ,
                                                :salivaIncreased ;
          OpenPVSignal:refers_to_concomitant_drug :valproicAcid ;
          OpenPVSignal:refers_to_patient :Patient12 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :methylphenidate ,
                                                        :ziprasidone ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report13
:Report13 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :drugInteraction ,
                                                :dyspnoea ,
                                                :dystonia ,
                                                :extrapyramidalDisorder ,
                                                :faceOedema ,
                                                :mentalDeficiency ,
                                                :muscleContractionsInvoluntary ,
                                                :musculoskeletalDisorder ,
                                                :neuralgia ,
                                                :pain ,
                                                :skeletalPain ,
                                                :speechDisorder ,
                                                :tachycardia ,
                                                :tendernessNos ,
                                                :tetany ;
          OpenPVSignal:refers_to_patient :Patient13 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :oxybutynin ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report14
:Report14 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :amphetaminesPositive ,
                                                :dystonia ,
                                                :tachycardia ,
                                                :therapeuticResponseIncreased ;
          OpenPVSignal:refers_to_concomitant_drug :hydrobromide ,
                                                  <http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#guaifenesin/dextromethorphan> ;
          OpenPVSignal:refers_to_patient :Patient14 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report15
:Report15 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :conditionAggravated ,
                                                :dystonia ,
                                                :muscleContractionsInvoluntary ;
          OpenPVSignal:refers_to_patient :Patient15 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 15" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report16
:Report16 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ,
                                                :medicineIneffective ,
                                                :muscleContractionsInvoluntary ;
          OpenPVSignal:refers_to_patient :Patient16 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 16" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report17
:Report17 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :accidentNos ,
                                                :dysphagia ,
                                                :dystonia ;
          OpenPVSignal:refers_to_concomitant_drug :risperidone ,
                                                  :sertraline ;
          OpenPVSignal:refers_to_patient :Patient17 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report18
:Report18 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                                :dizziness ,
                                                :dystonia ,
                                                :insomnia ,
                                                :muscleContractionsInvoluntary ,
                                                :nausea ,
                                                :somnolence ;
          OpenPVSignal:refers_to_concomitant_drug :loratadine ;
          OpenPVSignal:refers_to_patient :Patient18 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 18" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report19
:Report19 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ,
                                                :muscleContractionsInvoluntary ;
          OpenPVSignal:refers_to_concomitant_drug :risperidone ;
          OpenPVSignal:refers_to_patient :Patient19 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 19" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :coma ,
                                               :dystonia ,
                                               :tongueDisorderAilment ;
         OpenPVSignal:refers_to_concomitant_drug :valproicAcid ;
         OpenPVSignal:refers_to_patient :Patient2 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_secondary_suspect_drug :olanzapine ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report20
:Report20 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ;
          OpenPVSignal:refers_to_concomitant_drug :lamotrigine ;
          OpenPVSignal:refers_to_patient :Patient20 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
          rdfs:label "Report 20" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report21
:Report21 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ,
                                                :extrapyramidalDisorder ,
                                                :jawDisorder ,
                                                :muscleContractionsInvoluntary ;
          OpenPVSignal:refers_to_patient :Patient21 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 21" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report22
:Report22 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ,
                                                :paraesthesia ;
          OpenPVSignal:refers_to_patient :Patient22 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 22" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report23
:Report23 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :agitation ,
                                                :amnesia ,
                                                :anxiety ,
                                                :coma ,
                                                :convulsionsGrandMal ,
                                                :dystonia ,
                                                :headache ,
                                                :hypertension ,
                                                :oculogyricCrisis ,
                                                :tachycardia ,
                                                :tongueBiting ,
                                                :urinaryIncontinence ;
          OpenPVSignal:refers_to_concomitant_drug :bupropion ,
                                                  :fluoxetine ;
          OpenPVSignal:refers_to_patient :Patient23 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :fluoxetine ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 23" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report24
:Report24 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ,
                                                :extrapyramidalDisorder ;
          OpenPVSignal:refers_to_patient :Patient24 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :methylphenidate ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 24" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report25
:Report25 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ;
          OpenPVSignal:refers_to_concomitant_drug :valproicAcid ;
          OpenPVSignal:refers_to_patient :Patient25 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :risperidone ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 25" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report26
:Report26 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dyskinesia ,
                                                :dystonia ;
          OpenPVSignal:refers_to_patient :Patient26 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :acetylsalicylicAcid ,
                                                        :risperidone ,
                                                        :valproicAcid ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 26" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report27
:Report27 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ;
          OpenPVSignal:refers_to_concomitant_drug :periciazine ;
          OpenPVSignal:refers_to_patient :Patient27 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 27" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report28
:Report28 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :anxiety ,
                                                :dystonia ;
          OpenPVSignal:refers_to_concomitant_drug :fluticasone ,
                                                  :paracetamol ,
                                                  :salbutamol ,
                                                  :salmeterol ;
          OpenPVSignal:refers_to_patient :Patient28 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 28" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report29
:Report29 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :diarrhoeaBloody ,
                                                :dystonia ,
                                                :extrapyramidalDisorder ,
                                                :fatigue ,
                                                :gastritis ,
                                                :hepaticEnzymesIncreased ,
                                                :oedemaGeneralised ,
                                                :urineAbnormal ,
                                                :vomiting ,
                                                :weightDecrease ;
          OpenPVSignal:refers_to_concomitant_drug :risperidone ;
          OpenPVSignal:refers_to_patient :Patient29 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 29" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :agitation ,
                                               :anxiety ,
                                               :asthenia ,
                                               :drugLevelChanged ,
                                               :dystonia ,
                                               :nausea ,
                                               :painInExtremity ,
                                               :paraesthesia ,
                                               :sgotIncreased ,
                                               :somnolence ;
         OpenPVSignal:refers_to_concomitant_drug :fluvoxamine ,
                                                 :quetiapine ;
         OpenPVSignal:refers_to_patient :Patient3 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report30
:Report30 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :aggressiveReaction ,
                                                :anxiety ,
                                                :choreoathetosis ,
                                                :coordinationAbnormal ,
                                                :cryingAbnormal ,
                                                :decreasedEyeContact ,
                                                :depression ,
                                                :dyskinesia ,
                                                :dystonia ,
                                                :emotionalLability ,
                                                :fatigue ,
                                                :homicidalIdeation ,
                                                :hyperkinesia ,
                                                :infectionBacterial ,
                                                :insomnia ,
                                                :medicineIneffective ,
                                                :nervousness ,
                                                :oppositionalDefiantDisorder ,
                                                :sleepDisorder ,
                                                :speechDisorder ,
                                                :suicideIdeation ,
                                                :teeth-grinding ;
          OpenPVSignal:refers_to_patient :Patient30 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :amfetamine ,
                                                        :aripiprazole ,
                                                        :carbamazepine ,
                                                        :chlorpromazine ,
                                                        :clonidine ,
                                                        :dexamfetamine ,
                                                        :iloperidone ,
                                                        :lisdexamfetamine ,
                                                        :lithium ,
                                                        :methylphenidate ,
                                                        :quetiapine ,
                                                        :valproicAcid ,
                                                        :ziprasidone ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 30" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report31
:Report31 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :convulsions ,
                                                :dystonia ;
          OpenPVSignal:refers_to_patient :Patient31 ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          OpenPVSignal:refers_to_secondary_suspect_drug :risperidone ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 31" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                               :azotaemia ,
                                               :dyskinesia ,
                                               :dystonia ,
                                               :eyeAbnormality ,
                                               :eyeInjury ,
                                               :eyePenetration ,
                                               :fever ,
                                               :hypercalcaemia ,
                                               :leukocytosis ,
                                               :opisthotonos ,
                                               :pharyngitis ,
                                               :phosphataseAlkalineIncreased ,
                                               :therapeuticResponseIncreased ,
                                               :treatmentNoncompliance ,
                                               :varicella ,
                                               :vomiting ;
         OpenPVSignal:refers_to_patient :Patient4 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :dystonia ,
                                               :therapeuticResponseIncreased ;
         OpenPVSignal:refers_to_concomitant_drug <http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dexamfetaminesulfate/amfetaminesulfate/dexamfetaminesaccharate/AmfetamineAspartate(adderall)> ;
         OpenPVSignal:refers_to_patient :Patient5 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_secondary_suspect_drug :olanzapine ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :dystonia ,
                                               :hallucination ,
                                               :medicationError ,
                                               :muscleContractionsInvoluntary ;
         OpenPVSignal:refers_to_concomitant_drug <http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dexamfetaminesulfate/amfetaminesulfate/dexamfetaminesaccharate/AmfetamineAspartate(adderall)> ;
         OpenPVSignal:refers_to_patient :Patient6 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report7
:Report7 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :diplopia ,
                                               :dystonia ,
                                               :hallucination ,
                                               :medicationError ,
                                               :muscleContractionsInvoluntary ,
                                               :mydriasis ,
                                               :self-medication ;
         OpenPVSignal:refers_to_concomitant_drug <http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dexamfetaminesulfate/amfetaminesulfate/dexamfetaminesaccharate/AmfetamineAspartate(adderall)> ;
         OpenPVSignal:refers_to_patient :Patient7 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report8
:Report8 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :blepharospasm ,
                                               :dizziness ,
                                               :drugInteraction ,
                                               :dystonia ,
                                               :hypokinesia ,
                                               :speechDisorder ,
                                               :tremor ;
         OpenPVSignal:refers_to_concomitant_drug :levosalbutamol ;
         OpenPVSignal:refers_to_patient :Patient8 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report9
:Report9 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :dystonia ;
         OpenPVSignal:refers_to_concomitant_drug :risperidone ;
         OpenPVSignal:refers_to_patient :Patient9 ;
         OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report_a
:Report_a rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ;
          OpenPVSignal:refers_to_patient :Patient_a ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          rdfs:label "Report a" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Report_b
:Report_b rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ;
          OpenPVSignal:refers_to_patient :Patient_b ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          rdfs:label "Report b" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromAustralia
:ReportsFromAustralia rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Reports_group ;
                      OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                      OpenPVSignal:has_count 2 ;
                      OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Australia" ;
                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                      rdfs:label "Reports from Australia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromCanada
:ReportsFromCanada rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                   OpenPVSignal:has_count 1 ;
                   OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Canada" ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "Reports from Canada" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromGermany
:ReportsFromGermany rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                    OpenPVSignal:has_count 1 ;
                    OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Germany" ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "Reports from Germany" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromItaly
:ReportsFromItaly rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Reports_group ;
                  OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                  OpenPVSignal:has_count 1 ;
                  OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Italy" ;
                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                  rdfs:label "Reports from Italy" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromJapan
:ReportsFromJapan rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Reports_group ;
                  OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                  OpenPVSignal:has_count 1 ;
                  OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Japan" ;
                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                  rdfs:label "Reports from Japan" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromNewZealand
:ReportsFromNewZealand rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Reports_group ;
                       OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                       OpenPVSignal:has_count 1 ;
                       OpenPVSignal:refers_to_country "http://dbpedia.org/resource/New_Zealand" ;
                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                       rdfs:label "Reports from New Zealand" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromSouthAfrica
:ReportsFromSouthAfrica rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                        OpenPVSignal:has_count 2 ;
                        OpenPVSignal:refers_to_country "http://dbpedia.org/resource/South_Africa" ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        rdfs:label "Reports from South Africa" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromSpain
:ReportsFromSpain rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Reports_group ;
                  OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                  OpenPVSignal:has_count 1 ;
                  OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Spain" ;
                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                  rdfs:label "Reports from Spain" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromSwitzerland
:ReportsFromSwitzerland rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                        OpenPVSignal:has_count 1 ;
                        OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Switzerland" ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        rdfs:label "Reports from Switzerland" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsFromUnitedStates
:ReportsFromUnitedStates rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                         OpenPVSignal:has_count 20 ;
                         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         rdfs:label "Reports from United States" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsInVigibase
:ReportsInVigibase rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Free_text_reporting_element ;
                   mp:references :Ref.3 ;
                   OpenPVSignal:has_content """As of 1 September 2014, after the elimination of suspected duplicates, there are a total of 40 individual case safety reports (ICSRs) of dystonia in association with atomoxetine in the WHO Global ICSR database, VigiBaseÂ®. Out of these reports there are 31cases of dystonia in children and adolescents up to 17 years of age (Table 1). Of the remaining reports one is a 51 year old and one a 24 year old and the rest are have reported age unknown. The reports from children and adolescents were submitted from the United States (20 reports), Australia (2), South Africa (2), Canada, Germany, Italy, Japan, New Zealand, Spain and Switzerland (1 each). The patients ranged in age from 5 to 17 years with a median of 9 years. There were 23 males and 8 females. Atomoxetine was the only drug suspected in 21 of the 31 cases. There were other drugs also suspected in the remaining 10 cases and they included drugs for treatment of psychotic disorders in seven cases, drugs for treatment of depression (3 cases), epilepsy (3 cases) and ADHD (3 cases). In seven of these 10 cases, at least one of these drugs (olanzapine, ziprasidone, risperidone, chlorpromazine) is a likely cause. Antipsychotic drugs are a well-known cause of dystonia and the four drugs listed above all refer to dystonia as a possible adverse effect in their product information.3 Concomitant drugs were reported in 20 of the 31 cases and showed a similar trend to that observed with the co-suspected drugs with considerable use of antipsychotic, anticonvulsant, and antidepressant drugs along with the use of other treatments for ADHD. Time to onset was reported in only two of the reports and ranged from the same day the drug was administered to 24 days. The outcome of the dystonia was indicated in 17 reports. The patients were reported as recovered or recovering in 16 cases and not recovered in the remaining case. In the cases where recovery was reported, the drug was withdrawn in 13 cases, continued in one case and the fate of the drug was unknown in the remaining two cases. In the case where the patient had not recovered, the drug was continued. The indication for use was stated in 23 reports and indicated ADHD or a related disease in all 23 cases. Dosage ranged from 10 mg to 160 mg (median: 25 mg) in the 16 cases which reported this information. Other reactions were reported in 26 of the 31 reports. Other neuropsychiatric reactions were reported in 23 of those reports and six reports described gastrointestinal reactions. Changes in drug levels, changes in therapeutic response or medicine ineffective were reported in eight cases.  
""" ;
                   rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsNotRecovering
:ReportsNotRecovering rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Reports_group ;
                      OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                      OpenPVSignal:has_count 1 ;
                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                      OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                      rdfs:label "Reports not recovering " .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsWithAtomoxetineAsTheOnlySuspectDrug
:ReportsWithAtomoxetineAsTheOnlySuspectDrug rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Reports_group ;
                                            OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                                            OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
                                            OpenPVSignal:has_count 21 ;
                                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                            rdfs:label "Reports with atomoxetine as the only suspect drug" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsWithDechallenge
:ReportsWithDechallenge rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                        OpenPVSignal:has_count 13 ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                        OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
                        rdfs:label "Reports with recovery after drug withdrawl" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ReportsWithRecoveringAsOutcome
:ReportsWithRecoveringAsOutcome rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                                OpenPVSignal:has_count 2 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                                rdfs:label "Reports with recovery with unknown action" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Reports_with_ADHD_as_indication
:Reports_with_ADHD_as_indication rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:concerns_indication_for_use :attentionDeficitHyperactivityDisorder ;
                                 OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                                 OpenPVSignal:has_count 23 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "Reports with ADHD as indication" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Reports_with_dosage_info
:Reports_with_dosage_info rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                          OpenPVSignal:refers_to_dosage :DosageContent ;
                          OpenPVSignal:has_count 16 ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          rdfs:label "Reports with dosage info" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Reports_with_recovery_without_drug_withdrawl
:Reports_with_recovery_without_drug_withdrawl rdf:type owl:NamedIndividual ,
                                                       OpenPVSignal:Reports_group ;
                                              OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                                              OpenPVSignal:has_count 1 ;
                                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                              OpenPVSignal:refers_to_outcome_after_action "recovery without drug withdrawal" ;
                                              rdfs:label "Reports with recovery without drug withdrawl" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Reports_with_time_to_onset_info
:Reports_with_time_to_onset_info rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:is_subgroup_of :overallReportsInVigibaseForAdolescent ;
                                 OpenPVSignal:time_to_onset :timeToOnsetContent ;
                                 OpenPVSignal:has_count 2 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "Reports with time to onset info" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#SummaryContent
:SummaryContent rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Summary ;
                OpenPVSignal:has_content "Atomoxetine is a relatively potent inhibitor of the presynaptic noradrenaline transporter, a moderate inhibitor of 5HT uptake, and a weak inhibitor of dopamine uptake with minimal affinity for the other noradrenergic receptors. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as defined by DSM-IV criteria in children 6 years of age and older, adolescents and adults. After the elimination of suspected duplicates there are currently (1 September 2014) 31 individual case safety reports (ICSRs) in the WHO Global ICSR database, VigiBaseÂ® of dystonia in association with atomoxetine for children and adolescents up to 17 years of age. The reports are from Australia, Canada, Germany, Italy, Japan, New Zealand, South Africa, Spain, Switzerland and the United States. Atomoxetine was the only drug suspected in 21 of the 31 cases. The outcome of the dystonia was indicated in 17 reports. The patients were reported as recovered or recovering in 16 cases and not recovered in the remaining case. In the cases where recovery was reported, the drug was withdrawn in 13 cases, continued in one case and the fate of the drug was unknown in the remaining two cases. Case reports in VigiBaseÂ® suggest that there is a possible signal for the association of atomoxetine and dystonia. The fact there was a positive dechallenge in 13 of the 16 reports where recovery was documented is suggestive of a druginduced effect. However, the possible association of atomoxetine with dystonia appears restricted to the adolescent and paediatric population. A possible mechanism may be based on inhibition of dopamine uptake. " ;
                rdfs:label "Summary content" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#YoungAgeAsRiskFactorForatomoxetine-inducedDystonia
:YoungAgeAsRiskFactorForatomoxetine-inducedDystonia rdf:type owl:NamedIndividual ,
                                                             OpenPVSignal:Adverse_Effect_Mechanism ;
                                                    OpenPVSignal:refers_to_adverse_effect :dystonia ;
                                                    mp:references :Ref.3 ;
                                                    OpenPVSignal:has_content "It is also possible that children and adolescents may be at greater risk as it is known that younger age is a risk factor for the development of dystonia in patients receiving antipsychotic treatment.3" ;
                                                    rdfs:label "Young age as risk factor for atomoxetine-induced dystonia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#abdominalPain
:abdominalPain rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "R10.9" ;
               OpenPVSignal:has_MedDRA_code 10000081 ;
               OpenPVSignal:has_MedDRA_prefered_term "Abdominal pain" ;
               rdfs:label "abdominal pain" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#accidentNos
:accidentNos rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10000369 ;
             OpenPVSignal:has_MedDRA_prefered_term "Accident" ;
             rdfs:label "accident nos" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#acetylsalicylicAcid
:acetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Drug ;
                     OpenPVSignal:has_ATC_code "B01AC06" ,
                                               "N02BA01 " ;
                     rdfs:label "acetylsalicylic acid " .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#aggressiveReaction
:aggressiveReaction rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "F91.8" ;
                    OpenPVSignal:has_MedDRA_code 10001493 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Aggressive reaction" ;
                    rdfs:label "aggressive reaction" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#agitation
:agitation rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "R45.1" ;
           OpenPVSignal:has_MedDRA_code 10001497 ;
           OpenPVSignal:has_MedDRA_prefered_term "Agitation" ;
           rdfs:label "agitation" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#amfetamine
:amfetamine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06BA01" ;
            rdfs:label "amfetamine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#amnesia
:amnesia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "R41.3" ;
         OpenPVSignal:has_MedDRA_code 10001949 ;
         OpenPVSignal:has_MedDRA_prefered_term "Amnesia" ;
         rdfs:label "amnesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#amphetaminesPositive
:amphetaminesPositive rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_ICD_code "F15.20" ;
                      OpenPVSignal:has_MedDRA_code 10063228 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Amphetamines positive" ;
                      rdfs:label "amphetamines positive" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#anorexia
:anorexia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R63.0" ;
          OpenPVSignal:has_MedDRA_code 10002646 ;
          OpenPVSignal:has_MedDRA_prefered_term "Anorexia" ;
          rdfs:label "anorexia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#antipsychotics
:antipsychotics rdf:type owl:NamedIndividual ,
                         OpenPVSignal:DrugClass ;
                OpenPVSignal:has_ATC_code "N05A" ;
                rdfs:label "antipsychotics" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#anxiety
:anxiety rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "F41.9" ;
         OpenPVSignal:has_MedDRA_code 10002855 ;
         OpenPVSignal:has_MedDRA_prefered_term "Anxiety" ;
         rdfs:label "anxiety" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#aripiprazole
:aripiprazole rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "N05AX12" ;
              rdfs:label "aripiprazole" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#asthenia
:asthenia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R53" ;
          OpenPVSignal:has_MedDRA_code 10003549 ;
          OpenPVSignal:has_MedDRA_prefered_term "Asthenia" ;
          rdfs:label "asthenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#atomoxetin
:atomoxetin rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_mechanism :MechanismOfAtomoxetine ,
                                       :PossibleMechanismOfatomoxetine-inducedDystonia ;
            OpenPVSignal:has_ATC_code "Â N06BA09â" ;
            rdfs:label "atomoxetin" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#attentionDeficitHyperactivityDisorder
:attentionDeficitHyperactivityDisorder rdf:type owl:NamedIndividual ,
                                                OpenPVSignal:Indication ;
                                       OpenPVSignal:has_ICD_code "F90.0" ;
                                       OpenPVSignal:has_MedDRA_code 10003736 ;
                                       OpenPVSignal:has_MedDRA_prefered_term "Attention deficit/hyperactivity disorder" ;
                                       rdfs:label "attention deficit hyperactivity disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#azotaemia
:azotaemia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "R79.89" ;
           OpenPVSignal:has_MedDRA_code 10003885 ;
           OpenPVSignal:has_MedDRA_prefered_term "Azotaemia" ;
           rdfs:label "azotaemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#blepharospasm
:blepharospasm rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "G24.5" ;
               OpenPVSignal:has_MedDRA_code 10005159 ;
               OpenPVSignal:has_MedDRA_prefered_term "Blepharospasm" ;
               rdfs:label "blepharospasm" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#bupropion
:bupropion rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "N06AX12Â " ;
           rdfs:label "bupropion" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#buspirone
:buspirone rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "N05BE01Â " ;
           rdfs:label "buspirone" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#carbamazepine
:carbamazepine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "N03AF01Â " ;
               rdfs:label "carbamazepine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#chlorpromazine
:chlorpromazine rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "N05AA01" ;
                rdfs:label "chlorpromazine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#choreoathetosis
:choreoathetosis rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "G25.5" ;
                 OpenPVSignal:has_MedDRA_code 10008754 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Choreoathetosis" ;
                 rdfs:label "choreoathetosis" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#citalopram
:citalopram rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06AB04" ;
            rdfs:label "citalopram" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#clonidine
:clonidine rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "C02AC01" ;
           rdfs:label "clonidine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#coma
:coma rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_ICD_code "R40" ;
      OpenPVSignal:has_MedDRA_code 10010071 ;
      OpenPVSignal:has_MedDRA_prefered_term "Coma" ;
      rdfs:label "coma" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#conditionAggravated
:conditionAggravated rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "Â F91.8" ;
                     OpenPVSignal:has_MedDRA_code 10010264 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Condition aggravated" ;
                     rdfs:label "condition aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#convulsions
:convulsions rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "R56.8" ;
             OpenPVSignal:has_MedDRA_code 10010904 ;
             OpenPVSignal:has_MedDRA_prefered_term "Convulsion" ;
             rdfs:label "convulsions" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#convulsionsGrandMal
:convulsionsGrandMal rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "G40.309" ;
                     OpenPVSignal:has_MedDRA_code 10010918 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Convulsions grand mal" ;
                     rdfs:label "convulsions grand mal" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#coordinationAbnormal
:coordinationAbnormal rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_ICD_code "R27.8" ;
                      OpenPVSignal:has_MedDRA_code 10010947 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Coordination abnormal" ;
                      rdfs:label "coordination abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#cryingAbnormal
:cryingAbnormal rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "H04.209" ;
                OpenPVSignal:has_MedDRA_code 10011470 ;
                OpenPVSignal:has_MedDRA_prefered_term "Crying abnormal" ;
                rdfs:label "crying abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#d
:d rdf:type owl:NamedIndividual ,
            obo:OAE_0001182 ;
   OpenPVSignal:refers_to_adverse_effect :dystonia ;
   OpenPVSignal:refers_to_class :antipsychotics ;
   mp:references :Ref.3 ;
   OpenPVSignal:has_content "There were other drugs also suspected in the remaining 10 cases and they included drugs for treatment of psychotic disorders in seven cases, drugs for treatment of depression (3 cases), epilepsy (3 cases) and ADHD (3 cases). In seven of these 10 cases, at least one of these drugs (olanzapine, ziprasidone, risperidone, chlorpromazine) is a likely cause. Antipsychotic drugs are a well-known cause of dystonia and the four drugs listed above all refer to dystonia as a possible adverse effect in their product information.3" ;
   rdfs:label "Antipsychotics and dystonia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#decreasedEyeContact
:decreasedEyeContact rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "H52.7" ;
                     OpenPVSignal:has_MedDRA_code 10069633 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Decreased eye contact" ;
                     rdfs:label "decreased eye contact" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#decreased_apetite
:decreased_apetite rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "R63.0" ;
                   OpenPVSignal:has_MedDRA_code 10061428 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Decreased appetite" ;
                   rdfs:label "decreased appetite" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#decreased_weight
:decreased_weight rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "R63. 4" ;
                  OpenPVSignal:has_MedDRA_code 10047895 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Weight decreased" ;
                  rdfs:label "decreased weight" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#depression
:depression rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "F33" ;
            OpenPVSignal:has_MedDRA_code 10012378 ;
            OpenPVSignal:has_MedDRA_prefered_term "Depression" ;
            rdfs:label "depression" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dexamfetamine
:dexamfetamine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "N06BA02Â " ;
               rdfs:label "dexamfetamine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#diarrhoeaBloody
:diarrhoeaBloody rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "Â K92.1" ;
                 OpenPVSignal:has_MedDRA_code 10012741 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Diarrhoea haemorrhagic" ;
                 rdfs:label "diarrhoea bloody" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#diphenhydramine
:diphenhydramine rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Drug ;
                 OpenPVSignal:has_ATC_code "D04AA32Â " ;
                 rdfs:label "diphenhydramine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#diplopia
:diplopia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "H53.2" ;
          OpenPVSignal:has_MedDRA_code 10013036 ;
          OpenPVSignal:has_MedDRA_prefered_term "Diplopia" ;
          rdfs:label "diplopia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dizziness
:dizziness rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "R42" ;
           OpenPVSignal:has_MedDRA_code 10013573 ;
           OpenPVSignal:has_MedDRA_prefered_term "Dizziness" ;
           rdfs:label "dizziness" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#drugInteraction
:drugInteraction rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "T88.7XXA" ;
                 OpenPVSignal:has_MedDRA_code 10013710 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Drug interaction" ;
                 rdfs:label "drug interaction" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#drugLevelChanged
:drugLevelChanged rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "Z51.81" ;
                  OpenPVSignal:has_MedDRA_code 10013717 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Drug level changed" ;
                  rdfs:label "drug level changed" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#drugLevelDecreased
:drugLevelDecreased rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "R89.2" ;
                    OpenPVSignal:has_MedDRA_code 10013718 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Drug level decreased" ;
                    rdfs:label "drug level decreased" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dyskinesia
:dyskinesia rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "G24.01" ;
            OpenPVSignal:has_MedDRA_code 10013916 ;
            OpenPVSignal:has_MedDRA_prefered_term "Dyskinesia" ;
            rdfs:label "dyskinesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dysphagia
:dysphagia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "Â R13.10" ;
           OpenPVSignal:has_MedDRA_code 10013950 ;
           OpenPVSignal:has_MedDRA_prefered_term "Dysphagia" ;
           rdfs:label "dysphagia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dyspnoea
:dyspnoea rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R06.0" ;
          OpenPVSignal:has_MedDRA_code 10013968 ;
          OpenPVSignal:has_MedDRA_prefered_term "Dyspnoea" ;
          rdfs:label "dyspnoea" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dystonia
:dystonia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "G24" ;
          OpenPVSignal:has_MedDRA_code 10013983 ;
          OpenPVSignal:has_MedDRA_prefered_term "Dystonia" ;
          rdfs:label "dystonia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#eegAbnormal
:eegAbnormal rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "R94.01" ;
             OpenPVSignal:has_MedDRA_code 10014408 ;
             OpenPVSignal:has_MedDRA_prefered_term "Electroencephalogram abnormal" ;
             rdfs:label "eeg abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#emotionalLability
:emotionalLability rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "R45.86" ;
                   OpenPVSignal:has_MedDRA_code 10014555 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Emotional lability" ;
                   rdfs:label "emotional lability" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#extrapyramidalDisorder
:extrapyramidalDisorder rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_ICD_code "G25.9" ;
                        OpenPVSignal:has_MedDRA_code 10015832 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Extrapyramidal disorder" ;
                        rdfs:label "extrapyramidal disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#eyeAbnormality
:eyeAbnormality rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "H57.9" ;
                OpenPVSignal:has_MedDRA_code 10015903 ;
                OpenPVSignal:has_MedDRA_prefered_term "Eye abnormality" ;
                rdfs:label "eye abnormality" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#eyeInjury
:eyeInjury rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "S05" ;
           OpenPVSignal:has_MedDRA_code 10061128 ;
           OpenPVSignal:has_MedDRA_prefered_term "Eye injury" ;
           rdfs:label "eye injury" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#eyePenetration
:eyePenetration rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "S05.50XA" ;
                OpenPVSignal:has_MedDRA_code 10015960 ;
                OpenPVSignal:has_MedDRA_prefered_term "Eye penetration" ;
                rdfs:label "eye penetration" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#faceOedema
:faceOedema rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "R60.9" ;
            OpenPVSignal:has_MedDRA_code 10016029 ;
            OpenPVSignal:has_MedDRA_prefered_term "Face oedema" ;
            rdfs:label "face oedema" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#fatigue
:fatigue rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "R53" ;
         OpenPVSignal:has_MedDRA_code 10016256 ;
         OpenPVSignal:has_MedDRA_prefered_term "Fatigue" ;
         rdfs:label "fatigue" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#fever
:fever rdf:type owl:NamedIndividual ,
                OpenPVSignal:Adverse_Effect ;
       OpenPVSignal:has_ICD_code "R50.9" ;
       OpenPVSignal:has_MedDRA_code 10037660 ;
       OpenPVSignal:has_MedDRA_prefered_term "Pyrexia" ;
       rdfs:label "fever" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#fluoxetine
:fluoxetine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06AB03" ;
            rdfs:label "fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#fluticasone
:fluticasone rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "D07AC17" ;
             rdfs:label "fluticasone" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#fluvoxamine
:fluvoxamine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N06AB08Â " ;
             rdfs:label "fluvoxamine " .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#gastritis
:gastritis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "K29.70" ;
           OpenPVSignal:has_MedDRA_code 10017853 ;
           OpenPVSignal:has_MedDRA_prefered_term "Gastritis" ;
           rdfs:label "gastritis" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#gastrointestinal_reactions
:gastrointestinal_reactions rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Adverse_Effect ;
                            OpenPVSignal:has_MedDRA_code 10018011 ;
                            OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal symptom NOS" ;
                            rdfs:label "gastrointestinal reactions" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#hallucination
:hallucination rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "R44.3" ;
               OpenPVSignal:has_MedDRA_code 10019063 ;
               OpenPVSignal:has_MedDRA_prefered_term "Hallucination" ;
               rdfs:label "hallucination" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#headache
:headache rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R51" ;
          OpenPVSignal:has_MedDRA_code 10019211 ;
          OpenPVSignal:has_MedDRA_prefered_term "Headache" ;
          rdfs:label "headache" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#hepaticEnzymesIncreased
:hepaticEnzymesIncreased rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_ICD_code "R94.5" ;
                         OpenPVSignal:has_MedDRA_code 10060795 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Hepatic enzyme increased" ;
                         rdfs:label "hepatic enzymes increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#homicidalIdeation
:homicidalIdeation rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "Â R45.850" ;
                   OpenPVSignal:has_MedDRA_code 10049666 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Homicidal ideation" ;
                   rdfs:label "homicidal ideation" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#hydrobromide
:hydrobromide rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "N07XX59" ;
              rdfs:label "hydrobromide" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#hypercalcaemia
:hypercalcaemia rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "Â E83.52" ;
                OpenPVSignal:has_MedDRA_code 10020583 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hypercalcaemia" ;
                rdfs:label "hypercalcaemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#hyperkinesia
:hyperkinesia rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "I51.89Â " ;
              OpenPVSignal:has_MedDRA_code 10020651 ;
              OpenPVSignal:has_MedDRA_prefered_term "Hyperkinesia" ;
              rdfs:label "hyperkinesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#hypertension
:hypertension rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "I10" ;
              OpenPVSignal:has_MedDRA_code 10020772 ;
              OpenPVSignal:has_MedDRA_prefered_term "Hypertension" ;
              rdfs:label "hypertension" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#hypoaesthesia
:hypoaesthesia rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "R20.1" ;
               OpenPVSignal:has_MedDRA_code 10020937 ;
               OpenPVSignal:has_MedDRA_prefered_term "Hypoaesthesia" ;
               rdfs:label "hypoaesthesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#hypokinesia
:hypokinesia rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "I51.89" ;
             OpenPVSignal:has_MedDRA_code 10021021 ;
             OpenPVSignal:has_MedDRA_prefered_term "Hypokinesia" ;
             rdfs:label "hypokinesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#iloperidone
:iloperidone rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N05AX14" ;
             rdfs:label "iloperidone" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#increasedBloodPressure
:increasedBloodPressure rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_ICD_code "R03.0" ;
                        OpenPVSignal:has_MedDRA_code 10005750 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Blood pressure increased" ;
                        rdfs:label "increased blood pressure" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#increasedHeartRate
:increasedHeartRate rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10019303 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Heart rate increased" ;
                    rdfs:label "increased heart rate" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#infectionBacterial
:infectionBacterial rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "A49.9" ;
                    OpenPVSignal:has_MedDRA_code 10060945 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Bacterial infection" ;
                    rdfs:label "infection bacterial" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#insomnia
:insomnia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "G47.0" ;
          OpenPVSignal:has_MedDRA_code 10022437 ;
          OpenPVSignal:has_MedDRA_prefered_term "Insomnia" ;
          rdfs:label "insomnia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#irritability
:irritability rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "R45.4" ;
              OpenPVSignal:has_MedDRA_code 10022998 ;
              OpenPVSignal:has_MedDRA_prefered_term "Irritability" ;
              rdfs:label "irritability" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#jawDisorder
:jawDisorder rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "R68.84" ;
             OpenPVSignal:has_MedDRA_code 10061257 ;
             OpenPVSignal:has_MedDRA_prefered_term "Jaw disorder" ;
             rdfs:label "jaw disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#lamotrigine
:lamotrigine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N03AX09" ;
             rdfs:label "lamotrigine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#leukocytosis
:leukocytosis rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "D72.829" ;
              OpenPVSignal:has_MedDRA_code 10024378 ;
              OpenPVSignal:has_MedDRA_prefered_term "Leukocytosis" ;
              rdfs:label "leukocytosis" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#levosalbutamol
:levosalbutamol rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "âR03AC02â" ;
                rdfs:label "levosalbutamol" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#lisdexamfetamine
:lisdexamfetamine rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Drug ;
                  OpenPVSignal:has_ATC_code "N06BA12" ;
                  rdfs:label "lisdexamfetamine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#lithium
:lithium rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug ;
         OpenPVSignal:has_ATC_code "N05AN01" ;
         rdfs:label "lithium " .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#loratadine
:loratadine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R06AX13" ;
            rdfs:label "loratadine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#medicationError
:medicationError rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "T50.901A" ;
                 OpenPVSignal:has_MedDRA_code 10027091 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Medication error" ;
                 rdfs:label "medication error" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#medicineIneffective
:medicineIneffective rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10013709 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Drug ineffective" ;
                     rdfs:label "medicine ineffective" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#mentalDeficiency
:mentalDeficiency rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "F79" ;
                  OpenPVSignal:has_MedDRA_code 10027351 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Mental deficiency" ;
                  rdfs:label "mental deficiency" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#mentalStatusChanges
:mentalStatusChanges rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "R41.82" ;
                     OpenPVSignal:has_MedDRA_code 10048294 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Mental status changes" ;
                     rdfs:label "mental status changes" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#methylphenidate
:methylphenidate rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Drug ;
                 OpenPVSignal:has_ATC_code "N06BA04" ;
                 rdfs:label "methylphenidate" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#moodSwings
:moodSwings rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "F39" ;
            OpenPVSignal:has_MedDRA_code 10027951 ;
            OpenPVSignal:has_MedDRA_prefered_term "Mood swings" ;
            rdfs:label "mood swings" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#muscleContractionsInvoluntary
:muscleContractionsInvoluntary rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Adverse_Effect ;
                               OpenPVSignal:has_ICD_code "M62.838" ;
                               OpenPVSignal:has_MedDRA_code 10028293 ;
                               OpenPVSignal:has_MedDRA_prefered_term "Muscle contractions involuntary" ;
                               rdfs:label "muscle contractions involuntary" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#musculoskeletalDisorder
:musculoskeletalDisorder rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_ICD_code "M62.9" ;
                         OpenPVSignal:has_MedDRA_code 10048592 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Musculoskeletal disorder" ;
                         rdfs:label "musculoskeletal disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#mydriasis
:mydriasis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "H57.04" ;
           OpenPVSignal:has_MedDRA_code 10028521 ;
           OpenPVSignal:has_MedDRA_prefered_term "Mydriasis" ;
           rdfs:label "mydriasis" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#nausea
:nausea rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_ICD_code "R11" ;
        OpenPVSignal:has_MedDRA_code 10028813 ;
        OpenPVSignal:has_MedDRA_prefered_term "Nausea" ;
        rdfs:label "nausea" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#nervousness
:nervousness rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "R45.0" ;
             OpenPVSignal:has_MedDRA_code 10029216 ;
             OpenPVSignal:has_MedDRA_prefered_term "Nervousness" ;
             rdfs:label "nervousness" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#neuralgia
:neuralgia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "M79.2" ;
           OpenPVSignal:has_MedDRA_code 10029223 ;
           OpenPVSignal:has_MedDRA_prefered_term "Neuralgia" ;
           rdfs:label "neuralgia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#oculogyricCrisis
:oculogyricCrisis rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "H51.8" ;
                  OpenPVSignal:has_MedDRA_code 10030071 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Oculogyric crisis" ;
                  rdfs:label "oculogyric crisis" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#oedemaGeneralised
:oedemaGeneralised rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "R60.1" ;
                   OpenPVSignal:has_MedDRA_code 10018092 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Generalised oedema" ;
                   rdfs:label "oedema generalised" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#olanzapine
:olanzapine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N05AH03" ;
            rdfs:label "olanzapine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#opisthotonos
:opisthotonos rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "R29.3" ;
              OpenPVSignal:has_MedDRA_code 10030899 ;
              OpenPVSignal:has_MedDRA_prefered_term "Opisthotonus" ;
              rdfs:label "opisthotonos" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#oppositionalDefiantDisorder
:oppositionalDefiantDisorder rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_ICD_code "F91.3" ;
                             OpenPVSignal:has_MedDRA_code 10056440 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Oppositional defiant disorder" ;
                             rdfs:label "oppositional defiant disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#overallReportsInVigibaseForAdolescent
:overallReportsInVigibaseForAdolescent rdf:type owl:NamedIndividual ,
                                                OpenPVSignal:Reports_group ;
                                       OpenPVSignal:is_subgroup_of :OverallReportsInVigibase ;
                                       OpenPVSignal:refers_to_adverse_effect :dystonia ;
                                       OpenPVSignal:refers_to_drug :atomoxetin ;
                                       OpenPVSignal:has_count 31 ;
                                       OpenPVSignal:has_count_of_men 23 ;
                                       OpenPVSignal:has_count_of_women 8 ;
                                       OpenPVSignal:has_max_age "17.0"^^xsd:float ;
                                       OpenPVSignal:has_median_age "9.0"^^xsd:float ;
                                       OpenPVSignal:has_min_age "5.0"^^xsd:float ;
                                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                       rdfs:label "overall reports in vigibase for adolescent" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#oxcarbazepine
:oxcarbazepine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "N03AF02" ;
               rdfs:label "oxcarbazepine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#oxybutynin
:oxybutynin rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "G04BD04" ;
            rdfs:label "oxybutynin" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#pain
:pain rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_ICD_code "G89.1" ;
      OpenPVSignal:has_MedDRA_code 10033371 ;
      OpenPVSignal:has_MedDRA_prefered_term "Pain" ;
      rdfs:label "pain" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#painInExtremity
:painInExtremity rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "M79.606" ;
                 OpenPVSignal:has_MedDRA_code 10033425 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Pain in extremity" ;
                 rdfs:label "pain in extremity" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#paracetamol
:paracetamol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N02BE01" ;
             rdfs:label "paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#paraesthesia
:paraesthesia rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "R20.2" ;
              OpenPVSignal:has_MedDRA_code 10033775 ;
              OpenPVSignal:has_MedDRA_prefered_term "Paraesthesia" ;
              rdfs:label "paraesthesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#percentageOfAtomoxetineCasesForAdolescents
:percentageOfAtomoxetineCasesForAdolescents rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Statistical_Entity ;
                                            OpenPVSignal:refers_to_drug :atomoxetin ;
                                            OpenPVSignal:has_value 0.723 ;
                                            rdfs:label "percentage of atomoxetine cases for adolescents" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#periciazine
:periciazine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N05AC01Â " ;
             rdfs:label "periciazine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#pharyngitis
:pharyngitis rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "J02.9" ;
             OpenPVSignal:has_MedDRA_code 10034835 ;
             OpenPVSignal:has_MedDRA_prefered_term "Pharyngitis" ;
             rdfs:label "pharyngitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#phosphataseAlkalineIncreased
:phosphataseAlkalineIncreased rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Adverse_Effect ;
                              OpenPVSignal:has_ICD_code "R74.8" ;
                              OpenPVSignal:has_MedDRA_code 10059570 ;
                              OpenPVSignal:has_MedDRA_prefered_term "Blood alkaline phosphatase increased" ;
                              rdfs:label "phosphatase alkaline increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#pruritus
:pruritus rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "L29" ;
          OpenPVSignal:has_MedDRA_code 10037087 ;
          OpenPVSignal:has_MedDRA_prefered_term "Pruritus" ;
          rdfs:label "pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :ConclusionContent ,
                                                   :DiscussionContent ,
                                                   :Dystonia ,
                                                   :IntroductionContent ,
                                                   :ReportsInVigibase ,
                                                   :SummaryContent ;
          OpenPVSignal:is_supported_by_individual_case_report :Report1 ,
                                                              :Report10 ,
                                                              :Report11 ,
                                                              :Report12 ,
                                                              :Report13 ,
                                                              :Report14 ,
                                                              :Report15 ,
                                                              :Report16 ,
                                                              :Report17 ,
                                                              :Report18 ,
                                                              :Report19 ,
                                                              :Report2 ,
                                                              :Report20 ,
                                                              :Report21 ,
                                                              :Report22 ,
                                                              :Report23 ,
                                                              :Report24 ,
                                                              :Report25 ,
                                                              :Report26 ,
                                                              :Report27 ,
                                                              :Report28 ,
                                                              :Report29 ,
                                                              :Report3 ,
                                                              :Report30 ,
                                                              :Report31 ,
                                                              :Report4 ,
                                                              :Report5 ,
                                                              :Report6 ,
                                                              :Report7 ,
                                                              :Report8 ,
                                                              :Report9 ,
                                                              :Report_a ,
                                                              :Report_b ;
          OpenPVSignal:is_supported_by_statistical_entity :OverallReportsInVigibase ,
                                                          :PercentageOfatomoxetine-dystoniaCasesForAdolescents ,
                                                          :ReportsFromAustralia ,
                                                          :ReportsFromCanada ,
                                                          :ReportsFromGermany ,
                                                          :ReportsFromItaly ,
                                                          :ReportsFromJapan ,
                                                          :ReportsFromNewZealand ,
                                                          :ReportsFromSouthAfrica ,
                                                          :ReportsFromSpain ,
                                                          :ReportsFromSwitzerland ,
                                                          :ReportsFromUnitedStates ,
                                                          :ReportsNotRecovering ,
                                                          :ReportsWithAtomoxetineAsTheOnlySuspectDrug ,
                                                          :ReportsWithDechallenge ,
                                                          :ReportsWithRecoveringAsOutcome ,
                                                          :Reports_with_ADHD_as_indication ,
                                                          :Reports_with_dosage_info ,
                                                          :Reports_with_recovery_without_drug_withdrawl ,
                                                          :Reports_with_time_to_onset_info ,
                                                          :overallReportsInVigibaseForAdolescent ,
                                                          :percentageOfAtomoxetineCasesForAdolescents ;
          OpenPVSignal:refers_to_adverse_effect :dystonia ;
          OpenPVSignal:refers_to_drug :atomoxetin ;
          OpenPVSignal:refers_to_primary_suspect_drug :atomoxetin ;
          mp:supportedByData :ADRs_for_atomoxetine_from_clinical_trials ,
                             :AtomoxetineAndNeuropsychiatricFrequentAE ,
                             :d ;
          OpenPVSignal:initially_identified_on "01/08/2015" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#quetiapine
:quetiapine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N05AH04Â " ;
            rdfs:label "quetiapine" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#risperidone
:risperidone rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N05AX08" ;
             rdfs:label "risperidone" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#salbutamol
:salbutamol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R03AC02" ;
            rdfs:label "salbutamol" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#salivaIncreased
:salivaIncreased rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "K11.7" ;
                 OpenPVSignal:has_MedDRA_code 10039424 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Salivary hypersecretion" ;
                 rdfs:label "saliva increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#salmeterol
:salmeterol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R03AC12" ;
            rdfs:label "salmeterol" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#sedation
:sedation rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10039897 ;
          OpenPVSignal:has_MedDRA_prefered_term "Sedation" ;
          rdfs:label "sedation" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#seizures
:seizures rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R56.8" ;
          OpenPVSignal:has_MedDRA_code 10039906 ;
          OpenPVSignal:has_MedDRA_prefered_term "Seizure" ;
          rdfs:label "seizures" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#self-medication
:self-medication rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "Z91.14" ;
                 OpenPVSignal:has_MedDRA_code 10050729 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Self-medication" ;
                 rdfs:label "self-medication" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#sertraline
:sertraline rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06AB06" ;
            rdfs:label "sertraline" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#sgotIncreased
:sgotIncreased rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "R74.0" ;
               OpenPVSignal:has_MedDRA_code 10040524 ;
               OpenPVSignal:has_MedDRA_prefered_term "SGOT increased" ;
               rdfs:label "sgot increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#skeletalPain
:skeletalPain rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "M79.1" ;
              OpenPVSignal:has_MedDRA_code 10006002 ;
              OpenPVSignal:has_MedDRA_prefered_term "Bone pain" ;
              rdfs:label "skeletal pain" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#skinReactions
:skinReactions rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "T78.40XA" ;
               OpenPVSignal:has_MedDRA_code 10040914 ;
               OpenPVSignal:has_MedDRA_prefered_term "Skin reaction" ;
               rdfs:label "skin reactions" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#sleepDisorder
:sleepDisorder rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "G47Â " ;
               OpenPVSignal:has_MedDRA_code 10040984 ;
               OpenPVSignal:has_MedDRA_prefered_term "Sleep disorder" ;
               rdfs:label "sleep disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#somnolence
:somnolence rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "R40" ;
            OpenPVSignal:has_MedDRA_code 10041349 ;
            OpenPVSignal:has_MedDRA_prefered_term "Somnolence" ;
            rdfs:label "somnolence" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#speechDisorder
:speechDisorder rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "F80.9" ;
                OpenPVSignal:has_MedDRA_code 10041466 ;
                OpenPVSignal:has_MedDRA_prefered_term "Speech disorder" ;
                rdfs:label "speech disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#suicideIdeation
:suicideIdeation rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "R45.851" ;
                 OpenPVSignal:has_MedDRA_code 10042458 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Suicidal ideation" ;
                 rdfs:label "suicide ideation" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#syncope
:syncope rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "R55" ;
         OpenPVSignal:has_MedDRA_code 10042772 ;
         OpenPVSignal:has_MedDRA_prefered_term "Syncope" ;
         rdfs:label "syncope" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#tachycardia
:tachycardia rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "R00.0" ;
             OpenPVSignal:has_MedDRA_code 10043071 ;
             OpenPVSignal:has_MedDRA_prefered_term "Tachycardia" ;
             rdfs:label "tachycardia" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#teeth-grinding
:teeth-grinding rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "G47.63" ;
                OpenPVSignal:has_MedDRA_code 10043182 ;
                OpenPVSignal:has_MedDRA_prefered_term "Teeth-grinding" ;
                rdfs:label "teeth-grinding" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#tendernessNos
:tendernessNos rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "R52" ;
               OpenPVSignal:has_MedDRA_code 10043224 ;
               OpenPVSignal:has_MedDRA_prefered_term "Tenderness" ;
               rdfs:label "tenderness nos" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#tetany
:tetany rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_ICD_code "R29.0" ;
        OpenPVSignal:has_MedDRA_code 10043380 ;
        OpenPVSignal:has_MedDRA_prefered_term "Tetany" ;
        rdfs:label "tetany" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#therapeuticResponseIncreased
:therapeuticResponseIncreased rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Adverse_Effect ;
                              OpenPVSignal:has_ICD_code "T88.7" ;
                              OpenPVSignal:has_MedDRA_code 10043415 ;
                              OpenPVSignal:has_MedDRA_prefered_term "Therapeutic response increased" ;
                              rdfs:label "therapeutic response increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#tics
:tics rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_ICD_code "F95.9" ;
      OpenPVSignal:has_MedDRA_code 10043833 ;
      OpenPVSignal:has_MedDRA_prefered_term "Tic" ;
      rdfs:label "tics" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#timeToOnsetContent
:timeToOnsetContent rdf:type owl:NamedIndividual ,
                             <http://www.w3.org/2006/time#DurationDescription> ;
                    OpenPVSignal:has_content "Time to onset was reported in only two of the reports and ranged from the same day the drug was administered to 24 days. " ;
                    rdfs:label "time to onset content" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#tongueBiting
:tongueBiting rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "S01.552A" ;
              OpenPVSignal:has_MedDRA_code 10050467 ;
              OpenPVSignal:has_MedDRA_prefered_term "Tongue biting" ;
              rdfs:label "tongue biting" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#tongueDisorderAilment
:tongueDisorderAilment rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_ICD_code "K14.9" ;
                       OpenPVSignal:has_MedDRA_code 10043951 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Tongue disorder" ;
                       rdfs:label "tongue disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#treatmentNoncompliance
:treatmentNoncompliance rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_ICD_code "Z91.19" ;
                        OpenPVSignal:has_MedDRA_code 10049414 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Treatment noncompliance" ;
                        rdfs:label "treatment noncompliance" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#tremor
:tremor rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_ICD_code "R25.1" ;
        OpenPVSignal:has_MedDRA_code 10044565 ;
        OpenPVSignal:has_MedDRA_prefered_term "Tremor" ;
        rdfs:label "tremor" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#urinaryIncontinence
:urinaryIncontinence rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "R32" ;
                     OpenPVSignal:has_MedDRA_code 10046543 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Urinary incontinence" ;
                     rdfs:label "urinary incontinence" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#urineAbnormal
:urineAbnormal rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "R82.99" ;
               OpenPVSignal:has_MedDRA_code 10062226 ;
               OpenPVSignal:has_MedDRA_prefered_term "Urine analysis abnormal" ;
               rdfs:label "urine abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#valproicAcid
:valproicAcid rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "N03AG01" ;
              rdfs:label "valproic acid" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#varicella
:varicella rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "Â B01" ;
           OpenPVSignal:has_MedDRA_code 10046980 ;
           OpenPVSignal:has_MedDRA_prefered_term "Varicella" ;
           rdfs:label "varicella" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#vomiting
:vomiting rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R11" ;
          OpenPVSignal:has_MedDRA_code 10047700 ;
          OpenPVSignal:has_MedDRA_prefered_term "Vomiting" ;
          rdfs:label "vomiting" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#weightDecrease
:weightDecrease rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "R63.4" ;
                OpenPVSignal:has_MedDRA_code 10047895 ;
                OpenPVSignal:has_MedDRA_prefered_term "Weight decreased" ;
                rdfs:label "weight decrease" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#ziprasidone
:ziprasidone rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N05AE04" ;
             rdfs:label "ziprasidone" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Response_from_Eli_Lilly_&_company
<http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#Response_from_Eli_Lilly_&_company> rdf:type owl:NamedIndividual ,
                                                                                                              OpenPVSignal:Response_to_Pharmacovigilance_Signal_Report ;
                                                                                                     OpenPVSignal:refers_to_pharmacovigilance_signal_report :Atomoxetine_and_Dystonia_in_paediatric_patients ;
                                                                                                     OpenPVSignal:has_content """Thank you for the opportunity to provide our comments on the thorough assessment conducted by Dr Boyd. Eli Lilly & Company (Lilly) routinely queries reported adverse events in databases (Lillyâs internal safety database and FDA Adverse Event Reporting System) for early signs of potential adverse drug reactions in patients treated with Lilly drugs. Lilly recognizes the importance of early signal detection and also acknowledges that database queries are only one method that can be employed. Additionally, Lillyâs reviews of the spontaneously reported adverse events involve medical assessment of the narratives where information provided and not captured in the standard fields often helps to refine the assessment. Consistent with the Uppsala Monitoring Centre, Lilly recognizes that signals are uncertain and preliminary in nature (Uppsala Monitoring Centre, Signals selected by UMC and the clinical review panel: How the process works). This is because, for any given adverse event report considered in generating a signal, there is no certainty that the adverse event was caused by the suspected drug. Rather, the adverse event could have resulted from the underlying condition being treated, a comorbid condition, a concomitant medication, or may simply be the result of chance. Treatment-emergent dystonias have been associated with reduced dopamine neurotransmission in the basal ganglia, as typically described with antipsychotic medications such as risperidone or quetiapine (Tarsy and Simon, 2006). In this respect, it is pertinent that atomoxetine and other attention deficit hyperactivity disorder (ADHD) medications are not infrequently given in conjunction with concomitant medications including antipsychotic medications to treat the commonly occurring comorbid conditions associated with ADHD. Furthermore, as Dr Boyd mentioned in his assessment, younger individuals may be at greater risk of developing dystonia when they receive antipsychotic treatment. Lilly agrees with Dr Boydâs observation that in seven of the 31 cases co-suspect antipsychotic medications were a likely cause. Lilly also agrees with Dr Boydâs comment that, upon review of the data in Table 1, concomitant drugs were reported in 20 of the 31 cases and that these showed a similar trend to that observed with the co-suspected drugs with considerable use of antipsychotic, anticonvulsant, and antidepressant drugs. This observation seems to indicate that, although not considered suspect per se, many cases involved concomitant medications that have been associated with dystonic or other similar movement effects and hence, may also possibly be confounded. Based on in vivo preclinical data, atomoxetine enhances dopamine release in the prefrontal cortex, but not in the basal ganglia (i.e. striatum; Bymaster et al. 2002). Therefore, the mechanism by which atomoxetine could stimulate an induced dystonia via the dopaminergic pathway is unclear. In the current report, no rechallenge information was included, so Lilly presumes that none of the case reports involved a rechallenge situation. Positive dechallenge was, however, described in 13 of the 16 reports where recovery was documented. The significance of this information is not entirely clear as it was not mentioned if atomoxetine alone was stopped or if any concomitant medications (neuroleptics, antidepressants, stimulants, or other drugs) were stopped at the same time as atomoxetine or if the dystonia events may have been treated with pharmacological intervention. All of these factors would confound the assessment. Although Lilly regularly conducts ongoing surveillance, including automated signal detection for all its medications, Lilly has not previously identified a signal for dystonia with atomoxetine from any of our available data sources, including clinical trials. As noted in Dr Boydâs evaluation, no reports of dystonia in association with atomoxetine could be found in the literature. Nevertheless, Lilly takes the information provided by the Uppsala Monitoring Centre seriously, and therefore, based on the possible signal reported by Dr Boyd, plans to conduct a comprehensive review of dystonia events in atomoxetine-treated patients.


 References 
1. Bymaster FP, Katner JS, Nelson DL, HemrickLuecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711. 
2. Tarsy D, Simon DK. Dystonia. N Engl J Med. 2006;355:818-829.""" ;
                                                                                                     rdfs:label "Response from Eli Lilly & company" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dexamfetaminesulfate/amfetaminesulfate/dexamfetaminesaccharate/AmfetamineAspartate(adderall)
<http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#dexamfetaminesulfate/amfetaminesulfate/dexamfetaminesaccharate/AmfetamineAspartate(adderall)> rdf:type owl:NamedIndividual ,
                                                                                                                                                                         OpenPVSignal:Drug ;
                                                                                                                                                                OpenPVSignal:has_ATC_code "N06BA01" ,
                                                                                                                                                                                          "Â âN06BA02" ;
                                                                                                                                                                rdfs:label "dexamfetamine sulfate/amfetamine sulfate/dexamfetamine saccharate/ amfetamine aspartate (adderall)" ,
                                                                                                                                                                           "dexamfetaminesulfate/amfetaminesulfate/dexamfetaminesaccharate/AmfetamineAspartate(adderall)" .


###  http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#guaifenesin/dextromethorphan
<http://purl.org/OpenPVSignal/Signals/2015_4_atomoxetine_dystonia#guaifenesin/dextromethorphan> rdf:type owl:NamedIndividual ,
                                                                                                         OpenPVSignal:Drug ;
                                                                                                OpenPVSignal:has_ATC_code "R05CA03" ,
                                                                                                                          "R05DA09" ;
                                                                                                rdfs:label "guaifenesin/dextromethorphan" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
